Project Details
Description
A Liquid Biopsy-Derived Proteogenomic Biomarker for 177Lu-PSMA Radioligand Therapy in Patients with Prostate Cancer
| Status | Active |
|---|---|
| Effective start/end date | 12/13/24 → 10/1/26 |
Funding
- NOVARTIS PHARMACEUTICALS CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.